Advertisement

Topics

Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ

19:00 EST 14 Feb 2018 | BioSpace

The deal includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology.

Original Article: Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ

NEXT ARTICLE

More From BioPortfolio on "Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...